You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 4,423,037


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,423,037
Title: Inhibitors of peptide hormone action
Abstract:The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein the three N-terminal amino acids are removed and zero or more of the next four N-terminal amino acids are removed sequentially from the N-terminus.
Inventor(s): Rosenblatt; Michael (Newton Highlands, MA), Potts, Jr.; John T. (West Newton, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Application Number:06/377,839
Patent Claims:1. A parathyroid hormone analogue, comprising:

a parathyroid peptide fragment wherein the three N-terminal amino acids and zero or more of the next four N-terminal amino acids are absent from a parathyroid hormone (PTH), from a parathyroid hormone fragment comprising at least the first 34 amino acids of said PTH, or from said parathyroid hormone or said parathyroid hormone fragment in which amino acid #34 is replaced with D- or L-tyrosine or in which amino acids #8 and #18 are each replaced with norleucine and amino acid #34 is replaced with D- or L-tyrosine, wherein the carboxy-terminal of said peptide fragment is optionally an amide, and wherein the N-terminal of said peptide fragment is optionally a D-amino acid.

2. The analogue of claim 1 wherein said PTH is bovine PTH (bPTH).

3. The analogue of claim 2 wherein said hormone fragment comprises amino acids 1-34 (bPTH (1-34)).

4. The analogue of claim 2 or 3 wherein amino acid #34 is replaced by either D- or L-tyrosine.

5. The analogue of claim 2 or 3 wherein the N-terminal amino acid of said peptide fragment is a D-amino acid.

6. The analogue of claim 2 or 3 wherein the carboxy-terminal amino acid of said peptide fragment is an amide.

7. The analogue of claim 1 wherein said analogue is [L-Tyr-34] bPTH (4-34) amide.

8. The analogue of claim 1 wherein said analogue is [L-Tyr-34] bPTH (5-34) amide.

9. The analogue of claim 1 wherein said analogue is [L-Tyr-34] bPTH (6-34) amide.

10. The analogue of claim 1 wherein said analogue is [L-Tyr-34] bPTH (7-34) amide.

11. The analogue of claim 1 wherein said analogue is [D-Tyr-34] bPTH (4-34) amide.

12. The analogue of claim 1 wherein said analogue is [D-Tyr-34] bPTH (5-34) amide.

13. The analogue of claim 1 wherein said analogue is [D-Tyr-34] bPTH (6-34) amide.

14. The analogue of claim 1 wherein said analogue is [D-Tyr-34] bPTH (7-34) amide.

15. The analogue of claim 1 wherein said analogue is [Nle-8, Nle-18, Tyr-34] bPTH (4-34) amide.

16. The analogue of claim 1 wherein said PTH is human PTH (hPTH).

17. The analogue of claim 16 wherein said hormone fragment comprises amino acids 1-34 (hPTH (1-34)).

18. The analogue of claim 16 or 17 wherein amino acid #34 is replaced by either D- or L-tyrosine.

19. The analogue of claim 16 or 17 wherein the N-terminal amino acid of said peptide fragment is a d-amino acid.

20. The analogue of claim 16 or 17 wherein the carboxy-terminal amino acid of said peptide fragment is an amide.

21. The analogue of claim 16 wherein said analogue is [L-Tyr-34] hPTH (4-34) amide.

22. The analogue of claim 16 wherein said analogue is [L-Tyr-34] hPTH (5-34) amide.

23. The analogue of claim 16 wherein said analogue is [L-Tyr-34] hPTH (6-34) amide.

24. The analogue of claim 16 wherein said analogue is [L-Tyr-34] hPTH (7-34) amide.

25. The analogue of claim 16 wherein said analogue is [D-Tyr-34] hPTH (4-34) amide.

26. The analogue of claim 16 wherein said analogue is [D-Tyr-34] hPTH (5-34) amide.

27. The analogue of claim 16 wherein said analogue is [D-Tyr-34] hPTH (6-34) amide.

28. The analogue of claim 16 wherein said analogue is [D-Tyr-34] hPTH (7-34) amide.

29. The analogue of claim 16 wherein said analogue is [Nl3-8, Nle-18, Tyr-34] hPTH (4-34) amide.

30. A method of inhibiting the action of parathyroid hormone, comprising:

administering a therapeutically effective amount of an analogue of claim 1 to a vertebrate.

31. The method of claim 30 wherein said hormone is bPTH.

32. The method of claim 30 wherein said hormone is hPTH.

33. The method of claim 30, wherein said hormone fragment comprises the N-terminal 34 amino acids of a parathyroid hormone.

34. The method of claim 33 wherein said hormone fragment comprises the N-terminal 34 amino acids of bPTH.

35. The method of claim 33 wherein said hormone fragment comprises the N-terminal 34 amino acids of hPTH.

36. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] bPTH (4-34) amide.

37. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] bPTH (5-34) amide.

38. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] bPTH (6-34) amide.

39. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] bPTH (7-34) amide.

40. The method of claim 30 wherein said peptide fragment is [D-Tyr-34] bPTH (4-34) amide.

41. The method of claim 30 wherein said peptide fragment is [D-Tyr-34] bPTH (5-34) amide.

42. The method of claim 30 wherein said peptide fragment is [D-Tyr-34] bPTH (6-34) amide.

43. The method of claim 30 wherein said peptide fragment is [D-Tyr-34] bPTH (7-34) amide.

44. The method of claim 30 wherein said peptide fragment is [Nle-8, Nle-18, Tyr-34] bPTH (4-34) amide.

45. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (4-34) amide.

46. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (5-34) amide.

47. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (6-34) amide.

48. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (7-34) amide.

49. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (4-34) amide.

50. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (5-34) amide.

51. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (6-34) amide.

52. The method of claim 30 wherein said peptide fragment is [L-Tyr-34] hPTH (7-34) amide.

53. The method of claim 30 wherein said peptide fragment is [Nle-8, Nle-18, Tyr-34] hPTH (4-34) amide.

54. An in vitro bioassy of parathyroid hormone, wherein a measured amount of the analogue of claim 1 inhibits binding a parathyroid hormone to a PTH receptor in vitro.

55. The method of claim 30, wherein said administering is for the treatment of hypercalcemia.

56. The method of claim 30, wherein said administering is for the diagnosing or treating of hyperparathyroidism.

57. The method of claim 56, wherein the hyperparathyroidism results in a hypercalcemic crisis.

58. The method of claim 56, wherein the hyperparathyroidism results in renal failure.

59. The method of claim 56, wherein a tumor produces a parathyroid hormone-like substance.

60. The method of claim 30, wherein said administering is for the treatment of an immune disease.

61. The method of claim 60, wherein the immune disease comprises inflammation.

62. The method of claim 60, wherein the immune disease comprises an allergic response.

63. The method of claim 60, wherein the immune disease comprises hyperactive lymphocytes.

64. The method of claim 30, wherein said administering is for the treatment of hypertension.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.